Monitor cash runway: at current burn rate (~$7.6M/quarter), cash plus upfront offering proceeds provide roughly 4 quarters of funding before additional capital is needed. Watch for clinical data readouts from the EVANGELINE trial and any progress on rare pediatric disease designations that could trigger a Priority Review Voucher.
Price Chart
Executive Summary
Atossa Therapeutics reported Q2 2026 net loss of $8.5M ($0.95 per share), beating consensus of $1.04 loss per share by ~8.7%. Cash and equivalents fell to $26.1M from $41.3M at year-end 2025, reflecting ongoing clinical spending. A registered direct offering raised $4.5M upfront with potential for $12M more from warrants, partially offsetting cash burn but adding dilution.
Key Financial Metrics
Key Facts
- Q2 2026 net loss per share of $(0.95) vs consensus $(1.04) — a beat of ~8.7%
- Cash and cash equivalents: $26.1M at June 30, 2026, down from $41.3M at Dec 31, 2025
- Registered direct offering raised $4.5M upfront (1.36M shares + warrants for up to 2.73M additional shares)
- Total operating expenses decreased to $8.7M from $9.0M year-over-year
- R&D expenses fell 11% to $4.9M, while G&A rose 7% to $3.8M due to legal fees
- Enrollment completed in Phase 2 EVANGELINE trial of (Z)-endoxifen in breast cancer
Financial Impact
EPS beat of ~$0.09 vs consensus; cash burn of ~$15.2M in H1 2026; $4.5M upfront offering proceeds
Risk Factors
- Cash burn rate may accelerate with ongoing clinical trials, requiring further dilutive financing
- Dilution from the registered direct offering and warrant exercises (up to 2.73M additional shares)
- Clinical-stage biotech with no approved products; regulatory and trial execution risks for (Z)-endoxifen
- Patent litigation costs have been settled but legal expenses remain elevated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-339292 |
| Document: atos-20260807.htm | 0001193125-26-339292 |
| Document: 0001193125-26-339292-index-headers.html | 0001193125-26-339292 |
| Document: 0001193125-26-339292-index.html | 0001193125-26-339292 |
| Document: 0001193125-26-339292.txt | 0001193125-26-339292 |
| 8-K Data (Synthetic) | 0001193125-26-339292 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $2.44 | awaiting T+60 | — | $2.45 (+0.41%) |
Sep 29, 2026 27d ago | 8-K | $1.99 | awaiting T+60 | — | $2.45 (+23.12%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.45 (+8.89%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.45 (+0.41%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.45 (−57.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers